MARKET

CNTB

CNTB

Connect Biopharma Holdings Ltd
NASDAQ
2.370
-0.110
-4.44%
Opening 12:57 05/15 EDT
OPEN
2.420
PREV CLOSE
2.480
HIGH
2.480
LOW
2.330
VOLUME
75.88K
TURNOVER
--
52 WEEK HIGH
3.820
52 WEEK LOW
0.7000
MARKET CAP
149.22M
P/E (TTM)
-2.3776
1D
5D
1M
3M
1Y
5Y
1D
Connect Biopharma files to sell 6.13M ordinary shares for holders
TipRanks · 4h ago
BRIEF-Connect Biopharma Holdings Ltd - Proposed Resale Of Up To 6.1 Million Ordinary Shares Of Connect Biopharma - SEC Filing
Reuters · 7h ago
Connect Biopharma posts corporate presentation on rademikibart development in asthma, COPD, atopic dermatitis
PUBT · 1d ago
Analyst Reiterates Buy on Rademikibart, Citing Strong Clinical Profile, Large Market Opportunity and Unchanged $10 Price Target
TipRanks · 2d ago
Connect Biopharma to present at H.C. Wainwright BioConnect Investor Conference fireside chat
PUBT · 2d ago
Connect Biopharma Holdings (CNTB) Gets a Buy from H.C. Wainwright
TipRanks · 3d ago
Connect Biopharma reports Q1 EPS (34c), consensus (28c)
TipRanks · 3d ago
Connect Biopharma Hldgs Q1 EPS $(0.34) Misses $(0.28) Estimate, Sales $169.000K
Benzinga · 3d ago
More
About CNTB
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

Webull offers Connect Biopharma Holdings Ltd (ADR) stock information, including NASDAQ: CNTB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNTB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNTB stock methods without spending real money on the virtual paper trading platform.